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Recent progress in complex I research suggests that a wide variety of complex I inhibitors share a common large binding domain with
partially overlapping sites. To verify this concept, we carried out real-time displacement tests of a fluorescent ligand with various competitors
using a novel quinazoline-type inhibitor (aminoquinazoline, AQ). In the presence of an excess amount of the competitors, the binding of AQ
to the enzyme was completely suppressed, being in line with the concept mentioned above. However, AQ bound to the enzyme was not
displaced by subsequent addition of an increasing amount of competitors in the concentration range expected from the relative magnitude of
the Kd values of AQ and competitors, rather, much higher concentrations of the competitors were needed to displace bound AQ. These results
cannot be explained merely by the premise of a common or partially overlapping binding site(s) between AQ and competitors. On the other
hand, double-inhibitor titration of steady state complex I activity suggested that additivity of inhibition is not necessarily observed for all
pairs of complex I inhibitors. Our results are discussed in light of the cooperativity of the inhibitor binding sites.D 2003 Elsevier B.V. All rights reserved.Keywords: Complex I; Respiratory inhibitor; Structure–activity relationship1. Introduction
Mitochondrial proton-translocating NADH–ubiquinone
oxidoreductase (complex I) is located at the entry of the
respiratory chain, and recognized as one of the largest and
most complicated membrane-associated enzyme complexes
with a total mass close to 1000 kDa [1]. Recent mutagenesis
studies using the yeast Yarrowia lipolytica and Rhodobacter
capsulatus [2–4] and photoaffinity labeling studies [5,6]
indicated that PSST, ND5 and 49 kDa subunits contribute to
the inhibitor binding domain. However, our knowledge
about the electron-transport pathway, proton translocation
mechanism, and mode of action of numerous specific
inhibitors that are thought to compete for the quinone
binding site(s), is still largely limited.
A large number of inhibitors of complex I are known [7–
10]. With the exception of rhein [11] and diphenyleneiodo-
nium [12], which inhibit electron input into complex I, all
inhibitors act at the terminal electron transfer step of this
enzyme [7]. Radio- and fluorescent-ligand binding [13] and0005-2728/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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marker ligand is displaced by numerous competitors (i.e.
other complex I inhibitors). These findings are consistent
with the model of inhibitor binding sites proposed by Okun
et al. [13], wherein a wide variety of inhibitors share a
common large binding domain with partially overlapping
sites.
It should, however, be realized that in all these papers
[5,6,13], the authors demonstrated that the binding of a
certain marker ligand to the enzyme is completely sup-
pressed in the presence of an excess amount of competitors.
Under these experimental conditions, one cannot rule out
the possibility that even though the binding sites of the
ligand and competitors are quite different, the binding of an
excess amount of competitors induced structural change of
the ligand binding site, which resulted in suppression of the
ligand binding [14]. Actually, several studies suggested that
complex I undergoes dynamic conformational change [15–
18]. It remains, therefore, unclear how binding sites of
complex I inhibitors relate to each other. We thought that
a real-time displacement test of a marker ligand bound to the
enzyme by subsequent addition of an increasing amount of
competitor is necessary to better understand this issue. To
Fig. 1. Structure of AQ and DQA.
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itor with high fluorescence intensity should be useful. In the
present study, we synthesized a novel quinazoline-type
inhibitor (aminoquinazoline, AQ, Fig. 1), and examined
its mode of action with bovine heart mitochondrial complex
I in combination with other complex I inhibitors.2. Materials and methods
2.1. Materials
Piericidin A and bullatacin were generous gifts from Dr.
S. Yoshida (The Institute of Physical and Chemical Re-
search, Japan) and Dr. J. McLaughlin (Purdue University,
USA), respectively. Other chemicals were commercial prod-
ucts of analytical grade.
2.2. Synthesis of 6-amino-4-(4-tert-butylphenetylamino)qui-
nazoline (AQ)
4-Chloro-6-nitroquizazoline was synthesized by the
method of Endicott et al. [19]. 4-tert-Butylphenetylamine
was obtained by the LiAlH4 reduction of 4-tert-butylben-
zylnitril, which was prepared by reacting 4-tert-butylben-
zylbromide and NaCN, in dry THF in the presence of AlCl3
[20]. 4-(4-tert-Butylphenetylamino)-6-nitroquinazoline was
prepared by reacting the above two intermediates in benzene
in the presence of triethylamine (2 eq) under reflux over-
night. The resultant nitro derivative was reduced according
to Ref. [21] to afford AQ. 1H NMR (300 MHz, CDCl3) y
1.33 (s, 9 H), 3.00 (t, J = 7.0 Hz, 2 H), 3.85–4.00 (m, 4 H),
5.44 (br s, 1 H), 6.63 (d, J = 2.4 Hz, 1 H), 7.14 (dd, J = 2.4,
8.9 Hz, 1 H), 7.19 (d, J = 8.1 Hz, 2 H), 7.36 (d, J = 8.3 Hz, 2
H), 7.67 (d, J= 8.9 Hz, 1 H), 8.53 (s, 1 H). ESI-MS (m/z)
321 [M+H]+.
We also synthesized DQA used in the previous study
[13] to know its quantum yield and reexamine the fluores-
cence quenching titration. 1H NMR (300 MHz, CDCl3) y
0.85 (t, J = 6.9 Hz, 3 H), 1.31 (d, J= 6.5 Hz, 3 H), 1.20–
1.43 (m, 12 H), 1.63 (m, 2 H), 4.50 (qd, J = 6.6, 6.6 Hz, 1
H), 5.50 (br s, 1 H), 7.45 (ddd, J = 8.0, 8.0, 1.0 Hz, 1 H),7.75 (m, 2 H), 7.82 (d, J = 8.0 Hz, 1 H), 8.65 (s, 1 H). ESI-
MS (m/z) 286 [M+H]+.
2.3. NADH oxidase activity
Bovine heart submitochondrial particles (SMP) were
prepared by the method of Matsuno-Yagi and Hatefi [22]
using a sonication medium containing 0.25 M sucrose, 1
mM succinate, 1.5 mM ATP, 10 mM MgCl2, 10 mM MnCl2
and 10 mM Tris–HCl (pH 7.4), and stored in a buffer
containing 0.25 M sucrose and 10 mM Tris–HCl (pH 7.4)
at  84 jC. The content of complex I was calculated as the
minimal amount of bullatacin ( = rolliniastatin-2), the most
potent inhibitor of the enzyme [10,13], required to com-
pletely block the activity.
The NADH oxidase activity in SMP was followed
spectrometrically with a Shimadzu UV-3000 (340 nm,
e = 6.2 mM 1 cm 1) at 25 jC. The reaction medium (2.5
ml) contained 0.25 M sucrose, 1 mM MgCl2 and 50 mM
phosphate buffer (pH 7.4). The final mitochondrial protein
concentration was 30 Ag of protein/ml. The reaction was
started by adding 50 AM NADH after the equilibration of
SMP with inhibitor(s) for 5 min.
2.4. Fluorescence measurements
Fluorescence emission spectra were recorded on a
Hitachi RF-5000 spectrophotometer at 25 jC. For fluores-
cence quenching measurements, SMP were diluted in
phosphate buffer (0.25 M sucrose, 2 mM KCN, 1 mM
MgCl2 and 50 mM sodium phosphate, pH 7.4) to 1.25 mg
of protein/ml, corresponding to about 75 nM complex I.
AQ was added to a stirred quartz cuvette from ethanol
stock solution. The background fluorescence resulting from
SMP without AQ was subtracted from the spectral data to
correct for the effect of SMP. The excitation and emission
wavelengths were set at 360 and 480 nm, respectively,
with a slit width of 5 nm. The relative quantum yields of
AQ and DQA were determined in water using quinine
bisulfate in 0.1 M H2SO4 (quantum yield 0.55) as the
standard.3. Results
3.1. Analysis of AQ binding to complex I by fluorescence
quenching titration
The inhibitory potency and fluorescent properties of AQ
are listed in Table 1 along with those of DQA which was
used in Ref. [13]. AQ was shown to be superior to DQA in
terms of fluorescence properties. Notably, the much longer
excitation and emission wavelengths of AQ are convenient
for avoiding overlap with tryptophan fluorescence. We
carried out the fluorescence quenching titration using AQ
and DQA, as done in Ref. [13]. The typical titration given
Table 1
Characterization of AQ and DQA
IC50 (nM) kEX
max (nm) kEM
max (nm) Quantum yield
AQ 1.9 (F 0.2) 360 480 0.28
DQA 2.1 (F 0.2) 316a 360a < 0.01b
a From Ref. [13].
b Although quantum yield of DQA is very small in water, its
fluorescence intensity increases markedly in less polar organic solvents
(data not shown).
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completely quenched when AQ is bound to the enzyme.
The Kd and concentration of binding sites estimated as
described [13] were 12 (F 1.9) nM and 67 (F 10) nM,
respectively. The latter value was comparable to the con-
centration of complex I measured by inhibitor titration (see
Materials and methods). DQA gave a similar titration to
AQ, but with a shallower slope. When SMP were preincu-
bated with an excess amount (1–5 AM) of piericidin A,
bullatacin, rotenone, fenpyroximate or cap-44, the fluores-
cence of added AQ was not quenched, as shown in Fig. 2,
taking piericidin A as an example. This result indicates that
AQ could not bind to the specific binding site in the
presence of these competitors. We also confirmed this
phenomenon for DQA. These results are consistent with
those in Ref. [13].
However, under the above experimental conditions,
one cannot rule out the possibility that these inhibitors
prevent the binding of AQ by inducing a conformational
change in complex I, rather than occupying the same
binding domain, as mentioned in the Introduction. To
better understand this issue, it is necessary to examine
whether the AQ bound to the enzyme can be displaced by
subsequent addition of an increasing amount of compet-
itor. If AQ and a competitor have a common or over-
lapping binding site(s), and the site(s) maintains constant
affinities to both compounds during the binding equilib-Fig. 2. Fluorescence titrations of AQ and DQA with SMP. The ethanol
solution of AQ (closed circles) and DQA (closed squares) were sequentially
added to the suspension of SMP. After 4 min incubation at each
concentration, fluorescence emission was determined. SMP were preincu-
bated with 1 AM piericidin A for 4 min before the addition of AQ (open
circles) or DQA (open squares). Data shown are representative of three
independent experiments.rium, the amount of free AQ should increase with an
increase of the concentration of competitor added. Addi-
tionally, the concentration range of competitors required
to displace the bound AQ can be approximately expected
from the relative magnitude of the Kd values of AQ and
competitors.
We therefore examined whether the AQ bound to the
enzyme is displaced by subsequent addition of a competitor
using piericidin A, bullatacin, rotenone, cap-44, pyridaben
and fenpyroximate (Fig. 3). The concentration of AQ was
set to 0.15 AM in order to saturate the binding site as much
as possible while minimizing the amount of free (unbound)
form. Since the Kd value of AQ is slightly larger than that of
piericidin A, bullatacin, pyridaben and fenpyroximate [13],
addition of the competitors at an equivalent concentration to
AQ would be enough to significantly, if not completely,
displace the bound AQ. Unexpectedly, AQ was not dis-
placed by the addition of the competitors in the concentra-
tion range expected from the Kd values. Much higher
concentrations of bullatacin, piericidin A and fenpyroximate
were needed to displace the bound AQ. Rotenone and cap-
44, the Kd values of which are somewhat larger than the Kd
of AQ [13], didn’t displace bound AQ in the concentration
range studied. The experiments at higher concentrations
were impractical because of distortion of the fluorescence
spectra probably due to damage of the mitochondrial mem-
brane and limited solubility of the hydrophobic test com-
pounds. If we premise common or overlapping binding sites
between AQ and the competitors, these results suggest that
the site significantly loses inherent affinities to the compet-
itors during the binding equilibrium. Alternatively, we
cannot rule out the possibility that the binding site of AQ
may differ from that of the competitors, though both sites
affect each other by ligand binding, i.e. cooperativity takes
place.Fig. 3. Recovery of fluorescence emission of AQ by the addition of various
complex I inhibitors. After 4 min incubation of SMP with 0.15 AM AQ, the
ethanol solution of each complex I inhibitor was sequentially added to SMP.
After 4 min incubation at each concentration, fluorescence emission was
determined. The fluorescence intensity of 0.15 AM AQ without competitor
is set to zero. Bullatacin (open circles), piericidin A (closed circles),
fenpyroximate (triangles), rotenone (open squares), cap-44 (closed squares)
and pyridaben (double circles). Data shown are representative of at least
two independent experiments.
iophysica Acta 1605 (2003) 15–203.2. Double-inhibitor titration of steady state complex I
activity
To find a clue as to whether AQ and the competitors bind
to different sites, we examined the additivity of the inhibi-
tion of steady state complex I activity in combination of two
inhibitors, i.e. double-inhibitor titration. If the binding sites
of the two inhibitors are identical, the extent of inhibition by
the two will be additive and the maximum inhibition by one
inhibitor will be attained at a lower concentration than that
without an additional inhibitor. However, if the binding sites
are not identical and there is no cooperativity between the
two sites, the inhibition will not be additive and the
concentration giving maximum inhibition by one inhibitor
will not be affected irrespective of the additional inhibitor. A
typical example of double-inhibitor titration is seen in the
case of a combination of Qi and Qo inhibitors of cytochrome
bc1 complex [23,24], wherein the two sites are located at
different positions of the enzyme and work sequentially in
the enzyme turnover.
Fig. 4 shows double-inhibitor titration of different pairs
of complex I inhibitors with NADH oxidase activity. We
used bullatacin as the standard inhibitor because of its very
high binding affinity to complex I (Kd = 2–5 nM, Ref. [13])
and, as a result, the reproducible linearity of the titration
curve under the experimental conditions. In the presence of
piericidin A giving about 30% and 60% inhibition (Fig.
4A), complete inhibition by bullatacin was achieved at
significantly lower concentrations than those obtained with-
out piericidin A, indicating additivity of the inhibition
T. Ino et al. / Biochimica et B18Fig. 4. Inhibition of NADH oxidase activity by bullatacin. Titration by
bullatacin alone is shown by closed circles. Titration was performed in the
presence of piericidin A (panel A, 0.5 nM; open circles, 1.0 nM; open
squares) or rotenone (panel B, 1.6 nM; open circles, 3.8 nM; open squares).
Data shown are representative of two independent experiments.between the two inhibitors. We also observed this phenom-
enon between bullatacin and other acetogenin analogues or
pyridinium-type inhibitors (cf. Ref. [25]). By contrast, in the
presence of rotenone (Fig. 4B), bullatacin attained complete
inhibition at an identical concentration to that obtained
without rotenone. Similar titrations were observed for AQ,
fenpyroximate and cap-44, indicating a lack of additivity of
the inhibition between bullatacin and these inhibitors. As a
reference, titration by bullatacin was carried out in combi-
nation with diphenyleneiodonium, which is known to inhibit
electron input into complex I [12]. A similar titration with
that of rotenone was confirmed for this inhibitor (data not
shown). Among the inhibitors tested, the titration in the
presence of pyridaben was between the above two extremes
(data not shown).
Thus, when we take bullatacin as a reference inhibitor,
the additivity of inhibition is not necessarily observed for all
complex I inhibitors, suggesting the presence of multiple
inhibitor binding sites in complex I.4. Discussion
In the present study, we carried out two types of
fluorescence quenching titration using a novel quinazo-
line-type inhibitor, AQ. First, we examined whether AQ
can bind to complex I in the presence of an excess amount
of competitor. Second, we investigated whether bound AQ
can be displaced by subsequent addition of competitor. The
results obtained in the former experiments can be explained
if we premise that complex I inhibitors share a common
large binding domain with partially overlapping sites. How-
ever, the results observed in the latter experiments cannot be
interpreted solely by this scenario since much higher con-
centrations of competitors than expected from the Kd values
of AQ and the competitors were required. Some competitors
could not displace bound AQ under the experimental con-
ditions. The results of double-inhibitor titrations for NADH
oxidase activity are also complicated, that is, additivity of
the inhibition was not necessarily observed for all inhibitors.
To explain our results along with those of competition
tests in earlier works [5,6,13], we propose a model for the
inhibitor binding sites, as shown in Fig. 5. Our model is
largely based on that proposed by Okun et al. [13]. In this
model, we also premise that a wide variety of complex I
inhibitors share a common large binding domain (gray
circles), but the binding sites more or less differ depending
upon structural specificities of the inhibitors. We drew
‘‘two’’ binding sites (sites A and B) in the domain, whereas
this number itself is meaningless. It just means that the
binding sites are not identical for the sake of simplicity.
Additionally, we arranged the two sites in series with the
electron transfer pathway (Fig. 5(i)), not in parallel (Fig.
5(ii)), since all inhibitors attain complete inhibition by
themselves without an additional inhibitor. One important
difference of our model from that of Okun et al. [13] is the
Fig. 5. Model for the binding sites of complex I inhibitors acting at the terminal electron transfer step of the enzyme. A wide variety of complex I inhibitors
share a common large binding domain (gray circles). The binding of the first inhibitor represents full occupation of the site. The inhibitor binding induces
structural change of the binding site, and this structural change is also propagated to the adjacent inhibitor binding site, as shown by a shadowed arrow, i.e., the
two sites are cooperative in the inhibitor binding. It makes no difference to our model whether a certain competitor shares the same binding site with AQ or not.
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of the binding site, and this structural change is also
propagated to the adjacent inhibitor binding site, as shown
by a shadowed arrow in Fig. 5(iii) and (iv), i.e. the two sites
are cooperative in the inhibitor binding. It is notable that
several studies suggested dynamic conformational change of
complex I [15–18]. We also speculate that a certain inhib-
itor binds only to one of the two sites, not both sites. This
idea is supported by the homogeneity of the inhibition
behavior of complex I inhibitors [13,26] except cationic
pyridinium-type inhibitors [27–29]. It makes no difference
to our model whether a certain competitor shares the same
binding site with AQ or not. In Fig. 5(iii) and (iv), binding
of the first inhibitor represents full occupation of the site.
According to the model, we will describe each observa-
tion obtained in the present study. Firstly, we will consider
the observation that AQ could not bind to complex I in the
presence of an excess amount of competitor (Result 1). This
result is consistent with that in the earlier studies [5,6,13].
An excess amount of a certain competitor (first inhibitor)
occupies the site A or B, which results in the structural
change of its binding site. This structural change is propa-
gated to the adjacent site and, as a result, both sites lose their
inherent affinities to the second inhibitor (i.e. stoichiomet-
rically minor AQ) irrespective of the binding site of the
second inhibitor. Result 1 can be described according to this
scenario.
Next, we will take up the observation that bound AQ
could not be displaced by subsequent addition of compet-
itors (Result 2). AQ (first inhibitor) occupies site A or B,
which results in structural change of its binding site as
well. When the competitor (second inhibitor) shares the
same binding site with AQ (steps b and c), as the inherent
affinity of the site to the competitor is significantly dimin-
ished, high concentrations of the competitor are required to
displace the bound AQ like the case of bullatacin, or the
competitor no longer displaces bound AQ in the concen-tration range studied as in the case of rotenone (Fig. 3).
When the competitor does not share the binding site with
AQ (steps a and d), the binding affinity of the competitor is
diminished due to structural change induced by prior
binding of AQ. However, occupation of the adjacent
competitor binding site increases with an increase in the
concentration of competitor added. As the binding of
competitor to the adjacent site also affects the AQ binding
site, AQ is gradually displaced from its binding site with an
increase of concentration of the competitor. This scenario
describes Result 2.
Taken together, if we assume the cooperativity between
the different inhibitor binding sites, the results of fluores-
cence quenching titration can be explained. The results of
double-inhibitor titration are also explained on the basis of
the model of multiple binding sites. Additivity of the
inhibition is observed for the two inhibitors that share
the same binding site, but not for the inhibitors that do
not. As the inhibition behavior of substoichiometric
amounts of inhibitors for steady state complex I activity
was examined for the double-inhibitor titration, the extent
of saturation of the binding site by a competitor is
relatively low under the equilibrium conditions. Therefore,
the cooperativity of different binding sites may have little,
if any, effect on the explanation of the double-inhibitor
titration.
Although we here supposed structural changes of the
inhibitor binding sites induced by inhibitor binding, both the
nature and extent of the structural changes will vary depend-
ing upon the structural specificity of the inhibitors. In
addition, the number of inhibitor binding sites is not
necessarily restricted to two, as mentioned above. It is
therefore undoubted that quantitative analysis of the inhibi-
tion behavior of a pair of complex I inhibitors is highly
complicated. Nevertheless, we propose cooperativity be-
tween the inhibitor binding sites in order to describe the
inhibition behavior of a wide variety of complex I inhibitors.
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